

# Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)

NCT02781922

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	Metcela Inc.
<b>Enrollment</b>	40 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Functional single ventricle patient with heart failure who is scheduled for stage 2 (Glenn) or stage 3 (Fontan) surgery
- EF(%) by echocardiography  $\geq$  55%
- Able to obtain written informed consent of participation in the study by a parent of the patient

### Exclusion (15)

- Known medical history of cardiogenic shock
- Lethal, uncontrollable arrhythmia
- Complication of coronary artery disease
- Eisenmenger syndrome
- Complication of brain dysfunction due to circulatory failure

... and 10 more (see full listing online)

## Locations (4 total)

---

Kanagawa Children's Medical Center, Kanagawa, Japan  
Okayama University Hospital, Okayama, Japan  
Saitama Prefectural Children's Medical Center, Saitama, Japan  
... and 1 more locations